Aktiesnakken — Oktober 2010
-
hø - nu mangler vi bare at markedet finder ud af det, rytter...
-
kommer vi først i firstline i bare en enkelte indikation, så sker der ting og sager. Skidtet har jo ingen bivirkninger
-
jeg tager nu gerne en andel af ritux 30 mia DKK omsætning i kræftindikationer
-
Fantomas, - artiklen er på business.dk
-
Kommer det her bag på nogen... http://ekstrabladet.dk/kup/sundhed/article1430821.ece
-
den ser nu meget god stadigvæk - Genmab - 8 dage salgstal.....
-
rytter - og glem ikke kurslejet under cash værdien. Det burde borge for kursstigninger
-
respiratoren godt udtryk for alt under kurs 100
-
det tager godt nok lang tid at lade den salgstals-defibrillator.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind